Literature DB >> 1280573

Nutritional recommendations for diabetic patients and treatment with alpha-glucosidase inhibitors.

M Toeller1.   

Abstract

Adjunctive treatment with acarbose (possibLy together with sulphonylurea or insulin treatment) can be effectively utilised to achieve blood glucose control if postprandial hyperglycaemia is a problem and cannot be sufficiently controlled by dietary modifications. The alpha-glucosidase inhibitor, acarbose, should be taken with meals that are rich in complex carbohydrates and low in simple sugars, as recommended by diabetes associations, to achieve the greatest possible benefit from treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280573     DOI: 10.2165/00003495-199200443-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  14 in total

Review 1.  [Inhibitors of alpha-glucosidase].

Authors:  M Toeller
Journal:  Journ Annu Diabetol Hotel Dieu       Date:  1991

Review 2.  [Diabetes education].

Authors:  M Toeller
Journal:  Internist (Berl)       Date:  1990-03       Impact factor: 0.743

3.  Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view.

Authors:  K G Alberti; F A Gries
Journal:  Diabet Med       Date:  1988-04       Impact factor: 4.359

4.  Separate influence of dietary carbohydrate and fibre on the metabolic control in diabetes.

Authors:  G Riccardi; A Rivellese; D Pacioni; S Genovese; P Mastranzo; M Mancini
Journal:  Diabetologia       Date:  1984-02       Impact factor: 10.122

5.  Effect of source of dietary carbohydrate on plasma glucose and insulin responses to mixed meals in subjects with NIDDM.

Authors:  A M Coulston; C B Hollenbeck; A L Swislocki; G M Reaven
Journal:  Diabetes Care       Date:  1987 Jul-Aug       Impact factor: 19.112

6.  Hyperinsulinaemia--a possible risk factor for cardiovascular disease in diabetes mellitus.

Authors:  R W Stout
Journal:  Horm Metab Res Suppl       Date:  1985

Review 7.  Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  S P Clissold; C Edwards
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

Review 8.  Upper body adiposity and the risk for atherosclerosis.

Authors:  L F Van Gaal; G A Vansant; I H De Leeuw
Journal:  J Am Coll Nutr       Date:  1989-12       Impact factor: 3.169

9.  Sucrose malabsorption in man after ingestion of alpha-glucosidehydrolase inhibitor.

Authors:  W F Caspary
Journal:  Lancet       Date:  1978-06-10       Impact factor: 79.321

10.  Improvement of metabolic control in insulin dependent diabetics treated with the alpha-glucosidase inhibitor acarbose for two months.

Authors:  J Gérard; A S Luyckx; P J Lefebvre
Journal:  Diabetologia       Date:  1981-11       Impact factor: 10.122

View more
  4 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of Acarbose.

Authors:  T Salvatore; D Giugliano
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

Review 2.  Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.

Authors:  R Rabasa-Lhoret; J L Chiasson
Journal:  Drugs Aging       Date:  1998-08       Impact factor: 3.923

3.  d-Psicose Inhibits Intestinal alpha-Glucosidase and Suppresses the Glycemic Response after Ingestion of Carbohydrates in Rats.

Authors:  Tatsuhiro Matsuo; Ken Izumori
Journal:  J Clin Biochem Nutr       Date:  2009-08-28       Impact factor: 3.114

Review 4.  Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.

Authors:  Markolf Hanefeld
Journal:  Cardiovasc Diabetol       Date:  2007-08-15       Impact factor: 9.951

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.